Seagen Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Study of SGN-B6A in Advanced Solid Tumors
- Conditions
- Squamous Cell Carcinoma of Head and NeckHER2 Negative Breast NeoplasmsCutaneous Squamous Cell CancerExocrine Pancreatic AdenocarcinomaUterine Cervical NeoplasmsCarcinoma, Non-Small Cell LungEsophageal Squamous Cell CarcinomaUrinary Bladder NeoplasmsEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 824
- Registration Number
- NCT04389632
- Locations
- π¨π³
Taipei Veterans General Hospital, Taipei City, Other, Taiwan
πΊπΈAlaska Oncology and Hematology, Anchorage, Alaska, United States
πΊπΈHighlands Oncology Group, Fayetteville, Arkansas, United States
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT04254107
- Locations
- πΊπΈ
California Research Institute, Los Angeles, California, United States
πΊπΈUniversity of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
πΊπΈTexas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04227847
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Conditions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT04220203
A Study of SGN-CD228A in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT04042480
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈMD Anderson Cancer Center / University of Texas, Houston, Texas, United States
πΊπΈUniversity of Chicago Medical Center, Chicago, Illinois, United States
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT04032704
- Locations
- πΊπΈ
FirstHealth of the Carolinas, Pinehurst, North Carolina, United States
πΊπΈAdventist Health White Memorial, Los Angeles, California, United States
πΊπΈNorthwestern University, Chicago, Illinois, United States
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT03975647
- Locations
- πΊπΈ
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
πΊπΈUniversity of Texas Southwestern Medical Center, Dallas, Texas, United States
πΊπΈWinship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
A Safety Study of SGN-CD47M in Patients With Solid Tumors
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03957096
- Locations
- πΊπΈ
Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
πΊπΈMD Anderson Cancer Center / University of Texas, Houston, Texas, United States
πΊπΈProvidence Portland Medical Center, Portland, Oregon, United States
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03947255
- Locations
- πΊπΈ
Houston Methodist Cancer Center, Houston, Texas, United States
πΊπΈSCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States
πΊπΈSummit Medical Group, Florham Park, New Jersey, United States
A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03914755
- Locations
- πΊπΈ
PAREXEL International, Early Phase Clinical Unit - Los Angeles, Glendale, California, United States